University of Pittsburgh

The United States of America As Represented by the Secretary of

The Feinstein Institute for Medical Research

Timothy R Billiar

David A Geller

Richard L Simmons

Edith Tzeng

Andreas K Nussler

Larry L Shears, Ii

Howard David Edington

Kevin J Tracey

Larry K Keefer

Mitchell P Fink

Joseph E Saavedra

Yoram Vodovotz

Qi Mi

Gregory M Constantine

Lukas Schimunek

Allan Tsung

Rami Namas

Daolin Tang

Ling Zeng

Provided herein are methods for segregating trauma, e.g., blunt trauma, patients into different cohorts based on risk of multiple organ dysfunction syndrome using patient data obtained within a short time window following injury. The methods are useful in providing treatment to trauma patients, and for separating trauma patients into cohorts.

Time window-based platform for the rapid stratification of blunt trauma patients into distinct outcome cohorts

A method of treating a patient having an elevated inflammatory response, such as an elevated Type I interferon response, is provided. The method can be used to treat sepsis. The method comprises administering to a patient having an elevated inflammatory response, an inhibitor of anaplastic lymphoma kinase (ALK inhibitors) or expression of ALK, in an amount effective to treat the elevated inflammatory response.

Methods of treating conditions involving elevated inflammatory response

Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGBprotein within a time period sufficient to protect the organ or tissue from injury.

Use of HMGB1 for protection against ischemia reperfusion injury

The present invention provides a method of promoting the closure of a wound in a patient. This method involves transferring exogenous iNOS to the region of the wound whereby a product of iNOS is produced in the region of the wound to promote the closure of the wound. The present invention also provides a method of transplanting a graft into a patient, which method involves transferring a vector comprising an iNOS expression cassette to cells associated with the graft and surgically incorporating the graft tissue into the patient. Upon expression of iNOS within the patient, a product of iNOS is produced in the region of the graft to attenuate vasculopathy in the region of the graft.

Methods for promoting wound healing and treating transplant-associated

A human tissue inducible nitric oxide synthase cDNA clone is disclosed. A process for preparing this cDNA clone coding for human tissue inducible nitric oxide synthase and for expressing the human tissue inducible nitric oxide synthase protein are provided.

Isolated human inducible nitric oxide synthase

The present invention provides a method of promoting the closure of a wound in a patient. This method involves transferring exogenous iNOS to the region of the wound whereby a product of iNOS is produced in the region of the wound to promote the closure of the wound.

A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically effective amount of nitric oxide sufficient to protect the tissue from sepsis- or shock-induced injury.

Selective prevention of organ injury in sepsis and shock using selection

The present invention discloses a full-length human hepatocyte iNOS cDNA clone and various gene therapy applications utilizing an iNOS DNA sequence. In preferred embodiments of the disclosed invention, iNOS-directed gene therapy involves specific targeting of a DNA sequence encoding a protein or protein fragment with iNOS biological activity for treating vascular diseases and disorders, antitumor applications and in response to certain microbial infections.

Growing community of inventors

Pittsburgh, PA, United States of America

Timothy R Billiar